VEGFR

VEGFR inhibitors act on the receptor tyrosine kinases activated by vascular endothelial growth factor (VEGF). Three VEGF receptors (VEGFRs) regulate the growth of blood and lymphatic vessels. VEGFR2, also known as kinase insert domain receptor (KDR) or Flk-1, mediates most endothelial responses to VEGF-A, and VEGFR3 mainly controls lymphatic vessels. Mice lacking Flk-1 fail to form blood islands and blood vessels, which shows the central role of this receptor in vasculogenesis. Most compounds here bind the kinase domain and also inhibit related receptors such as the platelet-derived growth factor receptor (PDGFR) and c-Kit. Axitinib and SU 5416 (semaxinib) are used as VEGFR-focused tools, while lenvatinib and regorafenib cover broader kinase sets.

2 Items

  • PROTAC VEGFR-2 degrader-1
    Cat. No.
    A34841

    PROTAC VEGFR-2 degrader-1

    PROTAC VEGFR-2 Degrader-1 is a targeted protein degradation compound designed to selectively degrade VEGFR-2. It demonstrates minimal VEGFR-2 inhibition with an IC50 exceeding 1 μM, and exhibits limited anti-proliferative activity against EA.hy926 cells, with an IC50 greater than 100 μM. This reagent is valuable for research applications focused on the regulation of VEGFR-2 and its role in vascular biology and related disease mechanisms.

    Out of stock

    All 3 sizes
  • PROTAC VEGFR-2 degrader-2
    Cat. No.
    A34847

    PROTAC VEGFR-2 degrader-2

    PROTAC VEGFR-2 Degrader-2 primarily targets the vascular endothelial growth factor receptor 2 (VEGFR-2) for degradation through the PROTAC mechanism. This compound displays minimal inhibition of VEGFR-2 activity with an IC50 exceeding 1 μM and demonstrates anti-proliferative effects in EA.hy926 cells, with an IC50 greater than 100 μM. It serves as a valuable tool for studies focused on targeted protein degradation and the modulation of signaling pathways related to angiogenesis.

    Out of stock

    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...